Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H18Cl2N2O6S |
Molecular Weight | 413.274 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](COC(=O)CN)NC(=O)C(Cl)Cl
InChI
InChIKey=AMGKHLVPQHMHGQ-ZYHUDNBSSA-N
InChI=1S/C14H18Cl2N2O6S/c1-25(22,23)9-4-2-8(3-5-9)12(20)10(7-24-11(19)6-17)18-14(21)13(15)16/h2-5,10,12-13,20H,6-7,17H2,1H3,(H,18,21)/t10-,12-/m1/s1
Molecular Formula | C14H18Cl2N2O6S |
Molecular Weight | 413.274 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.mims.com/thailand/drug/info/urfamycinCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15224555 and https://www.drugs.com/international/urfamycin.html
Sources: http://www.mims.com/thailand/drug/info/urfamycin
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15224555 and https://www.drugs.com/international/urfamycin.html
Thiamphenicol aminoacetate is an antibiotic. It is the methyl-sulfonyl analogue of chloramphenicol and has a similar spectrum of activity, but is 2.5 to 5 times as potent. It is used in many countries as a veterinary antibiotic, but is available in China, Morocco and Italy for use in humans. Thiamphenicol aminoacetate is reported as an ingredient of Urfamycin in Ecuador, Indonesia, Italy, Taiwan, Thailand, Turkey, Japan. It is indicated for the treatment of GUT, hepatobiliary, respiratory tract, enteric tract infections, typhoid, paratyphoid fever and salmonellosis, brucellosis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Neisseria gonorrhoeae growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/2113717 |
|||
Target ID: Moraxella catarrhalis growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/11367873 |
|||
Target ID: Streptococcus pneumoniae growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/11367873 |
|||
Target ID: Haemophilus influenzae growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/11367873 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Urfamycin Approved UseGUT, hepatobiliary, resp tract, enteric tract infections, typhoid, paratyphoid fever & salmonellosis, brucellosis. |
|||
Curative | Urfamycin Approved UseGUT, hepatobiliary, resp tract, enteric tract infections, typhoid, paratyphoid fever & salmonellosis, brucellosis. |
|||
Curative | Urfamycin Approved UseGUT, hepatobiliary, resp tract, enteric tract infections, typhoid, paratyphoid fever & salmonellosis, brucellosis. |
PubMed
Title | Date | PubMed |
---|---|---|
[Re-evaluation of single-dose treatment with thiamphenicol and spectinomycin of uncomplicated male gonococcal urethritis]. | 1987 |
|
Comparative in vitro activity of thiamphenicol-glycinate and thiamphenicol-glycinate-acetylcysteinate and other antimicrobials against respiratory pathogens. | 2001 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.mims.com/thailand/drug/info/urfamycin
Adult 500 mg 8 hrly. Childn 20-30 mg/kg/day. Gonorrhea 2.5 g/day for 1-2 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11367873
THIAMPHENICOL AMINOACETATE inhibited M. catarrhalis with MIC90 0.5 ug/ml
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:07:02 GMT 2023
by
admin
on
Fri Dec 15 19:07:02 GMT 2023
|
Record UNII |
W5H94CY6V6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7048326
Created by
admin on Fri Dec 15 19:07:03 GMT 2023 , Edited by admin on Fri Dec 15 19:07:03 GMT 2023
|
PRIMARY | |||
|
C028813
Created by
admin on Fri Dec 15 19:07:03 GMT 2023 , Edited by admin on Fri Dec 15 19:07:03 GMT 2023
|
PRIMARY | |||
|
115817
Created by
admin on Fri Dec 15 19:07:03 GMT 2023 , Edited by admin on Fri Dec 15 19:07:03 GMT 2023
|
PRIMARY | |||
|
W5H94CY6V6
Created by
admin on Fri Dec 15 19:07:03 GMT 2023 , Edited by admin on Fri Dec 15 19:07:03 GMT 2023
|
PRIMARY | |||
|
2393-92-2
Created by
admin on Fri Dec 15 19:07:03 GMT 2023 , Edited by admin on Fri Dec 15 19:07:03 GMT 2023
|
PRIMARY | |||
|
100000084804
Created by
admin on Fri Dec 15 19:07:03 GMT 2023 , Edited by admin on Fri Dec 15 19:07:03 GMT 2023
|
PRIMARY | |||
|
163416
Created by
admin on Fri Dec 15 19:07:03 GMT 2023 , Edited by admin on Fri Dec 15 19:07:03 GMT 2023
|
PRIMARY | RxNorm | ||
|
2625
Created by
admin on Fri Dec 15 19:07:03 GMT 2023 , Edited by admin on Fri Dec 15 19:07:03 GMT 2023
|
PRIMARY | |||
|
SUB04801MIG
Created by
admin on Fri Dec 15 19:07:03 GMT 2023 , Edited by admin on Fri Dec 15 19:07:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |